Human Longevity Enhances Senior Leadership Team, Making Key Hires To Strengthen Commercialization And Operations

SAN DIEGO, May 2, 2017 /PRNewswire/ -- Human Longevity, Inc. (HLI) the genomics-powered, health intelligence company, announced today that several new senior staff have been hired to lead and continue to develop the company's growing portfolio of genomic based, CLIA-validated products and associated business strategy and operations. 

These key additions are: Travis Lacey, Chief Corporate Development Officer; Dale Gordon, Chief Commercial Officer; Gary G. Altman, Ph.D., Chief Operating Officer, who will all report to HLI CEO, Cynthia Collins and Steven Ness, D.O., client services strategist who reports to Dale Gordon.

Collins stated, "Over the last months HLI has launched several important products including our whole genome sequencing product to the insurance industry, our suite of oncology products, and we have continued to grow the HLI database of genomic and phenotypic data. We are at a pivotal point in the evolution of HLI and I am pleased to welcome Travis, Dale, Gary and Steveall seasoned business leadersto help me build on the sound science foundation and revolutionary technology at HLI."   

Travis Lacey Chief Corporate Development Officer
Travis Lacey has more than 20 years of experience in healthcare across functions including investment banking, business development, and operations. During his career, he has successfully led over fifty mergers and acquisitions and financing transactions with significant domain and functional expertise across the healthcare landscape, including pharma, devices and healthcare services.

Lacey joined HLI from GE Healthcare where he was managing director leading the divestiture practice and portfolio optimization across the $18B GE Healthcare platform. Prior to GE Healthcare, Lacey spent nine years in healthcare investment banking at Jefferies and Co., Inc. and Robert W. Baird & Co., Inc. where he was responsible for sourcing and leading merger and acquisitions and financing transactions. Prior to that, he spent the first ten years of his career at Abbott Laboratories where he held multiple positions across operations, manufacturing technology and quality.

Lacey received his Bachelor of Science in Statistics from University of Tennessee, Knoxville and his MBA from Northwestern University's Kellogg School of Management. 

Dale Gordon Chief Commercial Officer
Dale Gordon serves as chief commercial officer at Human Longevity. Prior to joining HLI, Gordon was most recently with GE Healthcare as the general manager of account management. There he was focused on the development and execution of commercial account management strategies, driving profitable growth and an improved customer experience across GE's Lab, Cell Therapy and Bioprocess businesses.

Before taking his position at GE, he had a long career at EMD Millipore, now MilliporeSigma and part of the Merck KGaA Group. There he served as head of regional (commercial) marketing in the Americas, responsible for developing and executing the regional marketing strategy across the multiplex and cytometry, lab water, separation and preparation, advanced analytics, life science reagents/antibodies, and biomonitoring portfolios. Other positons included head of North American sales, account management, head of global sales operations, global sales forces effectiveness manager, and area sales manager.

Gordon is a graduate of the University of Florida where he received a Bachelor of Science in Microbiology and Cell Science. He served on the board of directors at the Lab Product Association and served as chairman of their government affairs committee. He also serves on the board of directors at Small Steps for Compassion located in Tanzania, Africa.

Gary G. Altman, PhD Chief Operating Officer
Gary Altman has more than 25 years of experience in leading start-ups and global businesses from concept through commercialization. His experience includes roles as CEO, COO, VP and GM.

As co-founder and chief operating officer of a VC-backed drug discovery company, Altman raised $60M and advanced two drug candidates into human clinical trials. As general manager of a global business within a public corporation, Altman had P&L responsibility for $200M. He has initiated and led highly-productive relationships with diverse constituencies including academia, non-profits, and industry. Altman's experience spans a broad spectrum of technologies including cell therapy, therapeutics, and diagnostics.

He holds a PhD in Biochemistry and was a National Science Foundation post-doctoral fellow in the lab of Howard Temin, 1975 Nobel Laureate, at the University of Wisconsin, and served on the faculty of the MBA program at Johns Hopkins.

Steven Ness, D.O. Client Services Lead
Steven (Steve) Ness, DO has more than 17 years of experience leading marketing, medical affairs and client services teams in the diagnostic and life sciences fields. Most recently he served as director of client services at GE Healthcare's Clarient Diagnostics leading the department to industry-best customer service response times. Prior to joining GE, he held medical affairs and marketing positions at Quidel Corporation, Quest Diagnostics and Antech Diagnostics. In 2006 he co-founded Veterinary Diagnostics Institute, a veterinary reference laboratory, and launched the industry's 1st canine, feline and equine biomarker for heart disease and heart failure. The test was marketed under the brand name CardioCare. Idexx Laboratories purchased the rights to this test and now sells it under the Idexx CardioPet brand name.

Ness received a Bachelor of Science in Biology from Norwich University, Military College of Vermont, and his Doctor of Osteopathic Medicine degree from University of New England. He completed a pediatric internship at Balboa Naval Hospital in San Diego, CA. He served for five years as an active duty Navy physician stationed at Camp Pendleton where he was Regimental Surgeon for the 11th Marine Corps Regiment. There he had five Navy physicians under his leadership and was responsible for the healthcare of over 3,000 active duty U.S. Marines. He deployed to Iraq in support of Operation Iraqi Freedom. Ness was honorably discharged from the Navy at the rank of Lieutenant Commander.

About Human Longevity, Inc
Human Longevity, Inc. (HLI) is the genomic-based, health intelligence company empowering proactive healthcare and enabling a life better lived. HLI combines the largest database of genomic and phenotypic data with machine learning to drive discoveries and revolutionize the practice of medicine. HLI's business areas include the HLI Health Nucleus, a genomic powered clinical research center which uses whole genome sequence analysis, advanced clinical imaging and innovative machine learning, along with curated personal health information, to deliver the most complete picture of individual health; HLIQ Whole Genome and HLIQ Oncology. For more information, please visit http://www.humanlongevity.com or http://www.healthnucleus.com.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/human-longevity-inc-enhances-senior-leadership-team-making-key-hires-to-strengthen-commercialization-and-operations-300449887.html

SOURCE Human Longevity, Inc.